References
- BROWN J. S. Community-acquired pneumonia. Clinical medicine (London, England), 2012;12(6):538–543.
- KALANURIA A. A., ZIAI W., MIRSKI M. Ventilator-associated pneumonia in the ICU. Critical care (London, England). 2014;18(2):208.
- KARAKIOULAKI M., STOLZ D. Biomarkers in Pneumonia-Beyond Procalcitonin. International journal of molecular sciences. 2019;20(8):2004.
- BOBYLEV A. A., RACHINA S. A., AVDEEV S. N., KOZLOV R. S., MLADOV V. V. C-reactive protein evaluation in community acquired pneumonia with comorbid chronic heart failure as criterion of antibiotic prescription. Kardiologiia. 2019;59(2S):40–46.
- BARAK-CORREN Y., BARAK-CORREN N., GILELES-HILLEL A., HEIMAN E. The effect of C-reactive protein on chest X-ray interpretation: A decision-making experiment among pediatricians. Pediatric pulmonology. 2021;56(6):1644–1650.
- ULM L., HOFFMAN S., NABAVI D., HERMANS M., MACKERT B. M., HAMILTON F., et al. The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke. Frontiers in neurology. 2017;8:153.
- HELLYER T. P., MCAULEY D. F., WALSH T. S., ANDERSON N., CONWAY M. A., SINGH S., et al. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. The Lancet. Respiratory medicine. 2020;8(2):182–191.
- BUTLER C. C., GILLESPIE D., WHITE P., BATES J., LOWE R., THOMAS-JONES E., et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. The New England journal of medicine. 2019;381(2):111–120.
- STOLZ D., CHRIST-CRAIN M., BINGISSER R., LEUPPI J., MIEDINGER D., MULLER C., et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9–19
- BRIEL M., SCHUETZ P., MUELLER B., YOUNG J., SCHILD U., NUSBAUMER C., et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of internal medicine. 2008;168(18):2000–2008.
- LHOPITALLHIER L., KRONENBERG A., MEUWLY J. Y., LOCATELLY I., MUELLER Y., SENN N., et al. Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial. BMJ. 2021;374:n2132.
- MONTASSIER E., JAVAUDIN F., MOUSTAFA F., NANDJOU D., MAIGMAN M., HARDOUIN J., et al. Guideline-Based Clinical Assessment Versus Procalcitonin-Guided Antibiotic Use in Pneumonia: A Pragmatic Randomized Trial. Annals of emergency medicine. 2019;74(4):580–591.
- CHRIST-CRAIN M., STOLZ D., BINGISSER R., MULLER C., MIEDINGER D., HUBER P. R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American journal of respiratory and critical care medicine. 2006;174(1):84–93.
- WUSSLER D., KOZHUHAROV N., TAVARES OLIVEIRA M., BOSSA A., SABTI Z., NOWAK A., et al. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clinical chemistry. 2019;65(12):1532–1542.
- WIRZ Y., MEIER M. A., BOUADMA L., LUYT C. E., WOLFF M., CHASTRE J., et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Critical care (London, England). 2018;22(1):191.
- LONG W., DENG X., ZHANG Y., LU G., XIE J., TANG J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology (Carlton, Vic.). 2011;16(5):819–824.
- SCHUETZ P., CHRIST-CRAIN M., THOMANN R., FALCONNIER C., WOLBERS M., WIDMER I., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066.
- CHRIST-CRAIN M., JACCARD-STOLZ D., BINGISSER R., GENCAY M. M., HUBER P. R., TAMM M., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet (London, England). 2004;363(9409):600–607.
- Z. MAZLAN M., A. H. ISMAIL M., ALI S., SALMUNA Z. N., WAN M. SHUKERI W. F., OMAR M. Efficacy and safety of the point-of-care procalcitonin test for determining the antibiotic treatment duration in patients with ventilator-associated pneumonia in the intensive care unit: a randomised controlled trial. Anesthesiology intensive therapy. 2021;53(3):207–214.
- PIERRAKOS C., VELISSARIS D., BISDORFF M., MARSHALL J. C., VINCENT J. L. Biomarkers of sepsis: time for a reappraisal. Critical care (London, England). 2020;24(1):287.
- STOLZ D., SMYRNIOS N., EGGIMANN P., PARGGER H., THAKKAR N., SIEGEMUND M., et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. The European respiratory journal. 2009;34(6):1364–1375.
- OGASAWARA T., UMEZAWA H., NAITO Y., TAKEUCHI T., KATO S., YANO T., et al. Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory investigation. 2014;52(2):107–113.
- GAVAZZI G., DREVET S., DEBRAY M., BOSSON J. L., TIDADINI F., PACCALIN M., et al. Procalcitonin to reduce exposure to antibiotics and individualize treatment in hospitalized old patients with pneumonia: a randomised study. BMC geriatrics. 2022;22(1):965.
- DAUBIN C., VALETTE X., THIOLLIERE F., MIRA J. P., HAZERA P., ANNANE D., et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive care medicine. 2018;44(4):428–437.
- SAVVATEEVA E. N., RUBINA A. Y., GRYADUNOV D. A. Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management. BioMed research international. 2019;1701276.
- KAMAT I. S., RAMACHANDRAN V., ESWARAN H., GUFFEY D., MUSHER D. M. Procalcitonin to Distinguish Viral from Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;70(3):538–542.
- LIU D., SU L. X., GUAN W., XIAO K., XIE L. X. Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis. Respirology (Carlton, Vic.). 2016;21(2):280-288.
- SCHUETZ P., WIRZ Y., SAGER R., CHRIST-CRAIN M., STOLZ D., TAMM M. et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10(10):CD007498.
- AABENHUS R., JENSEN J.U., JORGENSEN K.J., HROBJARTSSON A., BJERRUM L. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2014;(11):CD010130.
- SCHUETZ P., BEISHUIZEN A., BROYLES M., FERRER R., GAVAZZI G., GLUCK E., et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clinical Chemistry and Laboratory Medicine (CCLM). 2019;57(9):1308-1318.
- SCHUETZ P., BALK R., BRIEL M., KUTZ A., CHRIST-CRAIN M., STOLZ D., et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med. 2015;53(4):583-592.
- WESTWOOD M., RAMAEKERS B., WHITING P., TOMINI F., JOORE M., ARMSTRONG N., et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015;19(96):v-236.